Healthcare
Live Price
Offline$34.76
+8.17% today
1Y Change
+162.37%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
10x Genomics, Inc. (TXG) is a Healthcare stock with a market cap of $2.89B and listed on NASDAQ. The stock last traded around $34.76 and up 162.4% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +5.2%, EPS growth of +77.0%, a dividend yield of 0.0%. What stands out right now is revenue +5.2%, EPS +77.0%, free cash flow +2371.2% with operating margin -9.5% and ROIC -6.8%. Valuation sits in the middle of the pack at price/sales 4.5. Stock Foundry combines TXG price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TXG
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TXG Max Drawdown
-28.03%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TXG and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$490.5M
-5.0% YoY
FY Net Income
-$58.2M
+64.9% YoY
Free Cash Flow
-$122.7M
+25.8% YoY
Revenue Growth
+5.2%
EPS Growth
+77.0%
Gross Margin
69.1%
Net Margin
-6.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 643M | 611M | 619M | 516M | 490M |
| Gross Profit | 444M | 414M | 409M | 396M | 416M |
| Operating Income | -111M | -195M | -265M | -168M | -53M |
| EBITDA | -111M | -134M | -205M | -128M | -25M |
| Net Income | -44M | -183M | -255M | -166M | -58M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 474M | 344M | 359M | 220M | 587M |
| Total Assets | 1.0B | 919M | 965M | 1.0B | 1.0B |
| Total Liabilities | 245M | 209M | 224M | 223M | 201M |
| Shareholder Equity | 796M | 710M | 741M | 806M | 818M |
| Total Debt | 158M | 83M | 95M | 95M | 82M |
| Net Debt | -316M | -261M | -264M | -125M | -505M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
21M
+36.4% YoY
Capital Expenditures
101M
+23.1% YoY
Free Cash Flow
123M
+25.8% YoY
Key ratios
Gross Margin
69.1%
Operating Margin
-9.5%
Net Margin
-6.8%
ROE
-5.7%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.